Floatz Rating
B59/100
Confidence
Indicative
Sponsor
Junpeng Wang
Modality
Small molecule
Development Phase
Phase 3
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
59High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07044336CT.gov Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01) | — | Recruiting | — | — | — |
NCT06813079CT.gov Using Tumor Models to Determine Treatments | — | Not Yet Recruiting | — | — | — |
NCT06687070CT.gov APG-2449 Monotherapy or in Combination With PLD in Patients With Platinum-resistant Recurrent OC or Advanced ST | — | Recruiting | — | — | — |
NCT05824975CT.gov A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08) | — | Recruiting | — | — | — |
NCT05275777CT.gov A Phase Ib Safety lead-in, Followed by Phase II Trial of ADG106 in Combination With Neoadjuvant Chemotherapy in HER2 Negative Breast Cancer | — | Active Not Recruiting | — | — | — |
NCT05279300CT.gov A Study of CS5001 in Patients With Advanced Solid Tumors and Lymphomas | — | Recruiting | — | — | — |
NCT04811118CT.gov The Comparison of the Pharmacokinetics of Albumin-bound Docetaxel and Taxotere | — | Unknown | — | — | — |
NCT04555837CT.gov Alisertib and Pembrolizumab for the Treatment of Patients With Rb-deficient Head and Neck Squamous Cell Cancer | — | Completed | — | — | — |
NCT03203525CT.gov Combination Chemotherapy and Bevacizumab With the NovoTTF-100L(P) System in Treating Participants With Advanced, Recurrent, or Refractory Hepatic Metastatic Cancer | — | Active Not Recruiting | — | — | — |
NCT04282018CT.gov Study of BGB-10188 as Monotherapy, and in Combination With Zanubrutinib, and Tislelizumab | — | Completed | — | — | — |
Show 37 more trialsShow fewer
NCT04172259CT.gov ACHP-THP vs EC-THP as Neoadjuvant Therapy for HER2-positive EBC | — | Active Not Recruiting | — | — | — |
NCT03678883CT.gov 9-ING-41 in Patients With Advanced Cancers | — | Active Not Recruiting | — | — | — |
NCT03387917CT.gov TLD-1, a Novel Liposomal Doxorubicin, in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT03034304CT.gov A Phase I Clinical Study for Evaluating the Safety and Efficacy of MASCT-I in Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02850822CT.gov Effect of Chemotherapy vs No Chemotherapy Pre-transplant to MDS Undergoing Allo-HSCT | — | Unknown | — | — | — |
NCT02644278CT.gov First-in-Human Study of the Safety, Tolerability, and Pharmacokinetic/Pharmacodynamic Profile of VX-984 in Combination With Chemotherapy | — | Completed | — | — | — |
NCT02367352CT.gov Alisertib (MLN8237) in Combination With Weekly Paclitaxel in East Asian Patients With Advanced Solid Tumors | — | Terminated | — | — | — |
NCT02331251CT.gov Study of Pembrolizumab Plus Chemotherapy in Patients With Advanced Cancer (PembroPlus) | — | Terminated | — | — | — |
NCT02259010CT.gov A Study to Evaluate the Effect of Itraconazole on the Pharmacokinetics of Alisertib in Participants With Advanced Solid Tumors or Relapsed/Refractory Lymphoma | — | Completed | — | — | — |
NCT02261805CT.gov A Phase I/II Study of Ganetespib in Combination With Doxorubicin | — | Terminated | — | — | — |
NCT02265510CT.gov An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies | — | Terminated | — | — | — |
NCT02214147CT.gov Pharmacokinetics of Alisertib in Adults With Advanced Solid Tumors or Relapsed/Refractory Lymphoma With Varying Degrees of Hepatic Function | — | Completed | — | — | — |
NCT02057380CT.gov A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial | — | Completed | — | — | — |
NCT01898078CT.gov Food Effect Study of Alisertib (MLN8237) in Participants With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT01815294CT.gov A Pivotal Bioequivalence Study of DOXIL/CAELYX (Doxorubicin HCL) in Patients With Advanced or Refractory Solid Malignancies Including Patients With Ovarian Cancer | — | Completed | — | — | — |
NCT01714947CT.gov Mass Balance, Pharmacokinetics and Metabolism Study of Alisertib | — | Completed | — | — | — |
NCT01715168CT.gov A Crossover Bioequivalence Study of Intravenously Administered ATI0918 and DOXIL/CAELYX in Patients With Ovarian Cancer | — | Unknown | — | — | — |
NCT01706835CT.gov Study to Investigate the Pharmacolkinetics of Aldoxorubicin (INNO-206;DOXO-EMCH) Administered as a 30 Minute Infusion Every 3 Weeks in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01673438CT.gov Phase 1b Study to Investigate the Safety and Maximum Tolerated Dose of Aldoxorubicin (INNO-206) Plus Doxorubicin HCL in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01512758CT.gov A Study of Alisertib (MLN8237) in Adult East Asian Participants With Advanced Solid Tumors or Lymphomas | — | Completed | — | — | — |
NCT01455532CT.gov A Dose Escalation Study of Iniparib as a Single Agent and in Combination in Solid Tumors | — | Completed | — | — | — |
NCT01337505CT.gov Safety and Maximum Tolerated Dose (MTD) Study of INNO-206 in Subjects With Advanced Solid Tumors | — | Completed | — | — | — |
NCT01094288CT.gov A Phase 1 Study of Alisertib Participants With Advanced Solid Tumors Including Castration-Resistant Prostate Cancer Receiving a Standard Docetaxel Regimen | — | Completed | — | — | — |
NCT01204996CT.gov A Study of the Safety and Efficacy of CNTO 888 in Combination With SoC (Standard of Care) Chemotherapy in Patients With Solid Tumors | — | Completed | — | — | — |
NCT00962091CT.gov Study of MLN8237 in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00798252CT.gov Ascending Multiple-Dose Study of Brivanib Alaninate in Combination With Chemotherapeutic Agents in Subjects With Advanced Cancers | — | Completed | — | — | — |
NCT00770536CT.gov AMG386 Comb w. Either Pegylated Liposomal Doxorubicin or Topotecan Subjects w. Advanced Recurrent Epithelial Ovarian CR | — | Completed | — | — | — |
NCT01131364CT.gov Combination Therapy of F16IL2 and Doxorubicin in Solid Tumour Patients | — | Terminated | — | — | — |
NCT00608803CT.gov Phase 1 Study of ZIO-201-T in Combination With Doxorubicin in Solid Tumors | — | Completed | — | — | — |
NCT00840385CT.gov Orally Fludarabine, Adriamycin and Dexamethasone (FAD) in Newly Diagnosed Peripheral T-cell Lymphomas (PTCL) | — | Unknown | — | — | — |
NCT00523380CT.gov Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer | — | Completed | — | — | — |
NCT01148628CT.gov Dose-finding Study of CAELYXTM and RAD001 in Patients With Advanced Solid Tumors | — | Unknown | — | — | — |
NCT00500903CT.gov A Study of MLN8237, a Novel Aurora A Kinase Inhibitor, in Participants With Advanced Solid Tumors | — | Completed | — | — | — |
NCT00305084CT.gov Study of NGR-hTNF in Combination With Doxorubicin in Solid Tumors | — | Completed | — | — | — |
NCT00147225CT.gov AMG 531 in Patients With Advanced Malignancy Receiving Treatment With Carboplatin | — | Completed | — | — | — |
NCT00525642CT.gov Study of Suitable Schedule of Docetaxel,Anthracycline and Cyclophosphamide in Adjuvant Therapy of Beast Cancer | — | Unknown | — | — | — |
NCT00183742CT.gov Trial of Liposomal Doxorubicin (Doxil) and Weekly Docetaxel (Taxotere) | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
59High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Cancer
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Adriamycin (this asset) | Junpeng Wang | P3 | B · 59 |
| Nabiximols | Jazz Pharmaceuticals | P3 | BBB |
| Pyridoxol | M.D. Anderson Cancer Center | P4 | BB |
| Rivoceranib | Jiangsu HengRui Medicine Co., Ltd. | P4 | BB |
| Desflurane | Peter MacCallum Cancer Centre, Australia | P4 | BB |
| Propofol | Hong Kong Children's Hospital | P4 | BB |
| Epirubicin | Zhejiang Provincial People's Hospital | P3 | BB |
| Atorvastatin | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | P2/3 | BB |
| Anamorelin | Helsinn Healthcare SA | P3 | BB |
+42 more in the Cancer cohort
Other indications for Adriamycin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Adult Acute Lymphoblastic Leukemia | — | P4 | BBB · 77 |
| B-Cell Childhood Acute Lymphoblastic Leukemia | — | P3 | BBB · 76 |
| Hematopoietic And Lymphoid System Neoplasm | — | P4 | BBB · 76 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Adriamycin in Cancer. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/adriamycin-cancer-9673
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →